Induction chemotherapy outcomes for acute myeloid leukemia (AML) remain less favorable in many low- and middle-income countries owing to delays in diagnosis, constrained supportive-care resources, and treatment-related complications. The authors set out to evaluate day-28 induction outcomes and to identify clinical, laboratory, infectious, comorbidity-related, and diagnostic predictors of unfavorable induction results in adults with newly diagnosed non-acute promyelocytic leukemia (non-APL) AML treated at a single tertiary-care network in Cairo, Egypt.
This observational cohort study enrolled 90 adult patients with newly diagnosed non-APL AML who received induction chemotherapy between January 2020 and December 2024 at Al-Azhar University Hospitals, Cairo, Egypt. The study design and timeframe are reported in the abstract; further specifics about enrollment criteria, exclusion criteria, or the process for consecutive inclusion are not detailed in the source abstract.
Day-28 induction outcomes were categorized into three mutually exclusive groups: complete remission (CR), refractory disease (R), or induction-related death (IID). For analysis purposes, an unfavorable induction outcome was defined as either refractory disease or induction-related death.
The investigators recorded a range of baseline data including demographic, clinical, and laboratory parameters as well as infectious status, comorbidities, immunophenotypic findings, and cytogenetic variables. The abstract indicates these categories were examined in both univariate and multivariate logistic regression models. The abstract does not provide the full list of specific variables entered into the multivariate models, nor does it present full descriptive tables for all collected parameters.
Among the 90 patients followed through day 28 after induction:
These outcome frequencies form the basis for the subsequent predictor analyses reported in the abstract.
Performance status measured by the Eastern Cooperative Oncology Group (ECOG) scale emerged as a significant predictor. Specifically, an ECOG performance status of ≥2 was associated with an increased likelihood of an unfavorable induction outcome in both univariate and multivariate analyses (univariate OR 4.58, 95% CI 1.74–12.08, P = 0.002; multivariate OR 3.96, 95% CI 1.39–11.27, P = 0.010).
On univariate analysis, additional baseline features associated with poorer induction outcomes included severe thrombocytopenia (platelet count <50 ×10^3/µL) and higher peripheral blood blast burden. The abstract does not report whether these variables remained significant in the multivariate model or provide adjusted odds ratios for them.
The abstract truncates while beginning to report results related to comorbidities and infectious complications; the remaining associations and detailed effect estimates for comorbid conditions, specific infectious complications, immunophenotypic markers, and cytogenetic abnormalities are not presented in the available text.
The authors used univariate and multivariate logistic regression models to examine associations between baseline variables and unfavorable induction outcome (refractory disease or IID). The abstract reports selected odds ratios, confidence intervals, and P values for ECOG performance status. Details on model selection strategy (for example, variable entry criteria), handling of missing data, goodness-of-fit metrics, and the complete list of covariates included in multivariate analyses are not provided in the source abstract.
The study frames its findings within the broader challenges that can worsen induction outcomes in resource-limited environments: delayed diagnosis, constrained supportive-care infrastructure, and complications related to treatment. Identification of ECOG performance status, severe thrombocytopenia, and high peripheral blast count as correlates of unfavorable early induction response underscores the importance of baseline clinical status and hematologic burden when planning induction and supportive strategies.
The abstract provides key outcome frequencies and highlights a strong independent association of poor performance status (ECOG ≥2) with unfavorable induction outcome. However, several relevant details are not reported in the available abstract and therefore cannot be stated definitively here. Missing information includes: the specific induction regimens used, detailed supportive-care protocols, definitions and rates of documented infectious complications beyond aggregated categories, full multivariate model results for other predictors (including comorbidities and cytogenetics), data on time to diagnosis or treatment delays, and subgroup analyses. The abstract itself appears truncated in the source at a point where additional results were about to be reported; those additional results and any author conclusions beyond what is cited here were not included in the accessible text.
From the abstracted information, the authors conclude that a substantial proportion of patients with non-APL AML did not achieve CR by day 28 or experienced induction-related death, and that poor ECOG performance status (≥2) was an independent predictor of unfavorable induction outcome. Severe thrombocytopenia and high peripheral blast burden were also associated with worse outcomes on univariate analysis. The study highlights the importance of baseline clinical status and the challenges faced in low- and middle-income settings when interpreting induction outcomes.
Note: For full methodological details, complete multivariate results, and the authors' full discussion and recommendations, the full-text article should be consulted; those details were not reported in the PubMed abstract available as the source for this rewrite.